Sanger sequencing News and Research

RSS

Updated data from ARIAD’s ponatinib pivotal trial on CML or Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced updated clinical data from the pivotal PACE trial of its investigational pan-BCR-ABL inhibitor, ponatinib, in patients with chronic myeloid leukaemia (CML) or Philadelphia-positive acute lymphoblastic leukaemia (Ph+ ALL), who are resistant or intolerant to dasatinib or nilotinib or who have the T315I mutation.

18 Jun 2012

Omixon Target, a next generation sequencing analysis software for targeted sequencing, released by Omixon

Today Omixon – a genomic software company - announced the commercial release of Omixon Target, a next generation sequencing analysis software for targeted sequencing. Omixon built its new software Target with the vision of helping diagnostic labs to adopt next generation sequencing to replace and complement traditional capillary Sanger sequencing.

30 May 2012

New breast cancer gene mutation discovered

A large international study led by University of Melbourne researchers has identified a mutation linked to breast cancer attached to the newly identified gene, called XRCC2. Lead researcher Melissa Southey said the discovery, using high-speed technology, would hopefully mean that more gene mutations responsible for causing breast cancer could be rapidly identified in the next few years.

1 Apr 2012

Pyromaker can rapidly sequence cancer-driving mutations

Using precise information about an individual's genetic makeup is becoming increasingly routine for developing tailored treatments for breast, lung, colon and other cancers. But techniques used to identify meaningful gene mutations depend on analyzing sequences of both normal and mutant DNA in tumor samples, a process that can yield ambiguous results. Now, a team of Johns Hopkins researchers says it has developed an easy-to-use online computer software application that can clear up any confusion faster and cheaper than other methods currently used to do the job.

16 Feb 2012

Pyromaker can more accurately identify complex genetic mutations

DNA sequencing to detect genetic mutations can aid in the diagnosis and selection of treatment for cancer. Current methods of testing DNA samples, Sanger sequencing and pyrosequencing, occasionally produce complex results that can be difficult or impossible to interpret. Scientists at the Johns Hopkins University School of Medicine have developed a free software program, Pyromaker, that can more accurately identify such complex genetic mutations.

6 Feb 2012

Life Technologies launches Ion AmpliSeq Cancer Panel

Life Technologies Corporation today announced the launch of the Ion AmpliSeq Cancer Panel, enabling scientists to sequence dozens of genes in cancer research samples using a simple workflow.

12 Oct 2011

Axeq announces Turnkey Discovery sequencing and analysis services

Axeq Technologies announced the industry-first Axeq Turnkey Discovery analytical bioinformatic services coupled with high-coverage exome sequencing applications.

15 Sep 2011

Transgenomic to present study results of high-sensitivity cancer mutation assays at AACR

Transgenomic, Inc. announced today that its scientists have completed studies employing the company's high-sensitivity cancer mutation assays using two proprietary technologies, Ice COLD-PCR and BLOCker-Sequencing. Results from these studies will be presented at the American Association for Cancer Research meeting in Orlando, Florida, April 2-6, 2011.

2 Apr 2011

Transgenomic discovers novel BLOCker-Sequencing technology

Transgenomic, Inc. today announced that it has discovered a novel sequencing technology, which the company has termed BLOCker-Sequencing, which enhances the limit of detection of standard Sanger Sequencing, enriches for direct sequencing of mutated DNA over wild-type and can be run on standard Sanger Sequencing equipment.

30 Mar 2011

CLC bio, Omixon release SOLiD Alignment plug-in for high-throughput sequencing data analysis

Today, CLC bio and Omixon announced the release of the Omixon Gapped SOLiD Alignment plug-in for full integration into CLC Genomics Workbench.

8 Feb 2011

New COLD-PCR technology to detect EGFR gene mutation

Transgenomic, Inc. today announced completion of a development study of several new assays to detect genetic mutations using the Company's proprietary Co-amplification at Lower Denaturing Temperature PCR (COLD-PCR) technology in the Epidermal Growth Factor Receptor (EGFR) gene.

8 Nov 2010

Researchers discover genetic alterations responsible for Kabuki syndrome

Using a new, rapid and less expensive DNA sequencing strategy, scientists have discovered genetic alterations that account for most cases of Kabuki syndrome, a rare disorder that causes multiple birth defects and mental retardation. Instead of sequencing the entire human genome, the new approach sequences just the exome, the 1-2 percent of the human genome that contains protein-coding genes.

16 Aug 2010

Positive results from study with Genome Sequencer FLX System for HIV drug-resistant mutation detection

454 Life Sciences, a Roche Company, has announced promising new results from a multi-site collaborative research study which used the company's Genome Sequencer FLX System to perform HIV drug-resistant mutation detection.

28 Jul 2010

SeqWright congratulates EraGen on successful FDA 510(k) market clearance of MultiCode-RTx HSV 1 & 2 Kit

EraGen Biosciences Inc., Madison, Wis., was congratulated today by SeqWright, Inc., Houston, on EraGen's successful FDA 510(k) market clearance of its MultiCode-RTx HSV 1 & 2 Kit. This new kit is the first FDA-cleared PCR-based qualitative in vitro diagnostic test for the detection and typing of HSV-1 and HSV-2 from vaginal lesion swab specimens in symptomatic female patients.

13 Jul 2010

Ambry Genetics introduces a suite of genetic tests to pinpoint the cause of mental retardation

Ambry Genetics today introduced The Ambry X-Linked Mental Retardation SuperPANEL™, a suite of genetic tests expected to pinpoint the cause of intellectual disability and X-linked mental retardation (XLMR).

24 Mar 2010

CLC bio releases groundbreaking whole-genome de novo assembler

Today, CLC bio released a groundbreaking whole-genome de novo assembler that will assemble genomes of any size, including human and plant genomes on a single workstation computer. Equally important, CLC bio’s de novo assembler is the first assembler that enables molecular biologists to set up, adjust, and run their large genome de novo assemblies through a graphical user-interface.

16 Mar 2010

Study validates Transgenomic's COLD-PCR technology for colorectal tumor-associated KRAS mutation detection

Transgenomic, Inc. announced today that it has completed a preliminary study with a leading pharmaceutical company that validates the use of its licensed COLD-PCR technology to detect colorectal tumor-associated KRAS mutations that determine efficacy of recently developed therapies. These were detected in plasma samples in which the mutation levels were too low for detection by standard DNA analysis methodologies such as Sanger sequencing.

9 Feb 2010

Presence of Streptococcus pneumoniae could predict risk of severe disease in H1N1 pandemic influenza

The presence of the Streptococcus pneumoniae in samples that can be easily obtained in clinics and emergency rooms may predict risk of severe disease in H1N1 pandemic influenza.

31 Dec 2009

MLL team finds 454 Sequencing technology promising for leukemia genetic characterization

This week at the 51st American Society for Hematology Annual Meeting, a team of researchers from the MLL Munich Leukemia Laboratory presented results from a series of groundbreaking studies which explore alternative, high-throughput 454 Sequencing methods for distinguishing and characterizing the many forms of leukemia and myeloproliferative disorders.

9 Dec 2009

Roche's high-throughput sequencing technology used for high-resolution HLA genotyping

A study published this month in the journal Tissue Antigens reports that researchers at Roche Molecular Systems in Pleasanton, CA have used high-throughput sequencing technology from 454 Life Sciences, a Roche Company, to carry out high-resolution human leukocyte antigen (HLA) genotyping in research samples.

27 Oct 2009